SOLICITATION NOTICE
B -- Services for Mutational Spectrum Analysis if the Birt-Hogg-Dube and Fumarate Hydratase Genes
- Notice Date
- 7/19/2005
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- RFQ-NCI-50096-NG
- Response Due
- 7/29/2005
- Archive Date
- 8/13/2005
- Small Business Set-Aside
- Total Small Business
- Description
- The National Cancer Institute, Division of Cancer Epidemiology and Genetics (DCEG), plans to procure services for Mutational Spectrum Analysis of the Birt-Hogg-Dube and Fumarate Hydratase Genes in Kidney Tumors from Cases Enrolled in the Eastern European Renal Cell Cancer Study. This requirement is being prepared in accordance with the format in FAR 12, Acquisition of Commercial Items. The acquisition will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial items. This acquisition is set aside for a Total Small Business. The North American Industry Classification Code is 541380 and the business size standard is $10M. Background: The National Cancer Institute (NCI) plans to conduct population studies to investigate the risk of changes of selected cancer susceptibility genes in sporadic kidney cancer. To accomplish this task, investigators at NCI in collaboration with the International Agency for Research on Cancer (IARC) are conducting a hospital-based case-control study of renal cell carcinoma (RCC) in six cities (Moscow, Bucharest, Lodi, Prague, Central Moravia and Bruno) across four Central and Eastern European countries. NCI plans to evaluate the mechanisms of inactivation of the fumarate hydratase (FH) and Birt-Hogg-Dube (BHD) genes in the etiology of RCC in cases from this study. To accomplish this task, we plan to screen DNA tumors samples for FH and BHD gene mutations. Contractor Requirement: 1) Design amplicons for each target fragment for analysis of exons of the FH and BHD genes, 2) Optimize PCR conditions for PCR amplification of all exons of the BHD and FH genes, 3) Screened PCR amplified samples for sequence variations, etc. Period of Performance: August 15, 2005 ? August 14, 2006 This is a firm fixed price contract. Interested parties may request a copy of the solicitation from Malinda Holdcraft, Contract Specialist via email at holdcram@exchange.nih.gov or via fax at 301-402-4513. Deadline date for requesting the solicitation is July 29, 2005, EDT. When requesting a copy of the solicitation, please provide a complete mailing address, point of contact, phone/fax numbers, email address and DUNS number. No collect calls will be accepted. Interested parties must refer to solicitation number RFQ-NCI-50096-NG. Please note any questions pertaining to this requirement must be directed to Malinda Holdcraft, Contract Specialist via electronic mail. In order to receive an award, contractors must be registered with the Central Contractor Registration (CCR) www.ccr.gov, and the Online Representations and Certifications Applications (ORCA) http://orca.bph.gov.
- Record
- SN00849862-W 20050721/050719211811 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |